问题 › 我们需要一份给银行的商业计划书 › 医疗服务提供商
贷款人阅读时关注的不是患者群体规模的雄心。他们关注的是，在最坏情况下，基于价值的合同下归属生命的债务是否仍能偿还。 对医疗服务提供商而言，难点在于结构：已在38,000名生命上承担下行风险，却缺乏按次成本数据来定价。因此任何可信方案都必须同时掌握按次成本与 payer mix，而这正是大多数内部分析停止的地方，因为两者分属不同系统。
贷款人阅读时关注的不是患者群体规模的雄心。他们关注的是，在最坏情况下，基于价值的合同下归属生命的债务是否仍能偿还。 对医疗服务提供商而言，难点在于结构：已在38,000名生命上承担下行风险，却缺乏按次成本数据来定价。因此任何可信方案都必须同时掌握按次成本与 payer mix，而这正是大多数内部分析停止的地方，因为两者分属不同系统。
给贷款人写的计划书常败在同一处：只有一个乐观情景，未显示按次成本的清晰算术。读者想确认的是，如果情况中度恶化，他们能否收回本金；而只有好情景的计划书，对测试38,000名归属生命毫无帮助。
能通过审查的是：有明确按次成本与患者群体规模假设的基础情景、一个真正糟糕而非温和缩减的下行情景，以及从经营表现到债务偿还的清晰对应。上行情景对每位提供商的贡献最不重要。
第二个败笔是不一致——收入线与归属生命的人头计划对不上，或营运资本未随 payer mix 变化而变动。贷款人靠读这类文件为生，这类问题他们很快就能发现。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 你需要在 CFO 或医务主任为银行设定的截止日期前拿到文件。
✓ 预测存在于电子表格中，且无人从外部用按次成本进行压力测试。
✓ 基于价值合同的下行情景不存在，或只是基础情景减去患者群体规模的百分之十。
通常会让情况更糟的做法。 把计划书写成有说服力，而不是让贷款人能在按次成本和 payer mix 上核查，这正是最快失去这类读者的方式。
It is for you if you run or finance a healthcare provider and you need the document by a deadline set by someone else. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 商业计划工作室, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
短到能读完，长到能被测试。财务数字及背后的假设决定结果；多余的叙述只会增加风险，不会增加信心。
现金流是否能在非乐观情景下偿还债务，以及数字内部是否自洽。几乎其他一切都只是这两点的背景。
匹配融资期限，第一年按月。超出贷款期限的细节只会显示不熟悉，而非严谨。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית